Abbreviated Name

APaCC - core funds for imaging biomarkers in PDAC

Lead Investigator

Koay, Eugene — The University of Texas MD Anderson Cancer

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Crichton, Dan — NASA Jet Propulsion Laboratory
• — Stanford University
• — University of Pittsburgh
• Maitra, Anirban — NYU Langone Health
• Li, Debiao — Cedars Sinai
• Von Hoff, Daniel — Translational Genomics Research Institute
• Rosenthal, Michael — Dana Farber Cancer Institute
• Goel, Ajay — City of Hope
• Majumder, Shounak — Mayo Clinic
• Zheng, Yingye — Fred Hutchinson Cancer Center
• Khalaf, Natalia — Baylor College of Medicine
• Alistar, Angela — Morristown Medical Center
• Koay, Eugene — The University of Texas MD Anderson Cancer

Abstract

Overview: This Core funding proposal aims to address critical areas for imaging biomarkers for early detection of PDAC. The first area involves the creation of technical validation datasets for repeatability and reproducibility, which are currently not available for early detection imaging biomarkers for PDAC. The second area involves the clinical validation of 3 imaging biomarker approaches for early detection of PDAC using a phase 3 biomarker design. The third area involves the creation of an ensemble autocontouring method for pancreas. This is also currently unavailable for imaging research related to PDAC early detection, and would be a useful resource of this consortium, as well as other imaging researchers.

Aims

1. Establish technical validation datasets of imaging biomarkers for PDAC early detection 2. Clinically validate imaging biomarkers that have undergone phase 2 biomarker evaluation.

Analytic Method

Model performance will be measured using the C-statistic, sensitivity, and specificity.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

Start Date

Jan 31 2024

Estimated Finish Date

Aug 31 2026

Protocol ID

540

Protocol Type

Validation

Fields of Research

• Other

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Malignant neoplasm of pancreas

Phased Status

3